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renchymal cells and chronic rejection. Certain of the describedIntragraft events preceding chronic renal allograft rejection in
immunopathologic findings (activation, proliferation, apopto-a modified tolerance protocol.
sis, and antibody deposition) may be useful in distinguishingBackground. Inbred miniature swine treated for 12 days
the type of rejection, that is, whether the allograft will progresswith high-dose cyclosporine A develop tolerance to histocom-
to chronic rejection or recovery.patibility complex (MHC) class I-mismatched renal allografts.
When this protocol was modified by adding thymectomy before
transplant, all animals developed acute rejection. Thereafter,
by day 100, one half developed chronic rejection (progression
Inbred miniature swine are the only large animal ingroup) and the other half recovered (recovery group). This
which one can reproducibly study the effects of selectiveprovides an excellent experimental model to identify the mech-
anisms of chronic rejection as well as the early changes that matching within the major histocompatibility complex
may predict chronic rejection. (MHC) on parameters of transplantation [1, 2]. They
Methods. We assessed the cellular infiltration, immune acti- also share many immunologic and physiologic propertiesvation, humoral immunity, and cell- and antibody-mediated
with humans and are useful for preclinical studies [2, 3].graft injury in the progression and the recovery groups. In
Our group demonstrated that inbred miniature swineaddition, we also examined circulating donor reactive cytotoxic
T lymphocyte (CTL) and antidonor antibody in both groups. treated with 12 days of high-dose cyclosporine A (CsA)
Results. From days 8 to 18 after transplantation, the two develop tolerance to MHC class II-matched, class I-mis-
groups were indistinguishable. Both showed acute rejection matched renal allografts [2, 4]. The thymus is necessarywith endarteritis (type II); had IgG and IgM deposition in
for rapid and stable tolerance induction in this model,glomeruli and small vessels; had an infiltrate with similar num-
presumably caused by central selection mechanismsbers of T cells, proliferating (PCNA1) and activated (interleu-
kin-2 receptor1) cells; and had a similar degree of parenchymal [5, 6]. If the protocol is modified by adding thymectomy
cell apoptosis [in situ DNA nick-end labeling (TUNEL)1]. 21 to 42 days prior to transplantation, only peripheral
However, by days 30 to 60, the two groups could be distin-
mechanisms of tolerance can operate. The thymectomyguished by several intragraft features. The recovery group be-
model may be relevant to the usual adult human withcame tolerant and had diminished T-cell infiltration, activation
and proliferation, and no detectable antibody deposition. The an atrophic thymus. These thymectomized pigs develop
number of TUNEL1-injured parenchymal cells decreased. In prolonged graft dysfunction with acute rejection on days
contrast, the progression group showed persistent cell infiltra- 8 to 18 [5, 6]. In 50% of animals, chronic rejection with
tion with activation and proliferation. Significantly prominent
graft dysfunction develops by day 100. In the remainingTUNEL1 apoptotic parenchymal cells in tubules, glomeruli,
50%, dysfunction improves gradually with the develop-peritubular capillaries and arteries were seen from day 30 to
day 100. Circulating donor reactive CTL and antidonor class ment of transplant tolerance, presumably by more effec-
I IgG were detected in the progression group at higher levels tive peripheral mechanisms.
than in the recovery group from days 30 to 60. Chronic rejection is one of the leading and intractableConclusion. In tolerance-induction protocols, unstable tol-
causes of renal allograft loss. Despite its devastating im-erance induction is associated with the persistent immunologic
pact on graft survival, the pathogenesis of chronic rejec-activation that mediates immunologic destruction of graft pa-
tion is still unclear and is believed to be multifactorial,
including immunologic and nonimmunologic factorsKey words: apoptosis, anti-MHC class I antibody, transplantation, cy-
[7–10]. Chronic rejection is often preceded by acute re-totoxic T cell, kidney rejection prediction, parenchymal cells, major
histocompatibility complex, xenograft model. jection [11–13], however, not all acute rejection episodes
lead to chronic rejection. The morphological and immu-Received for publication December 23, 1999
nologic features that promote or predict progression ofand in revised form May 2, 2000
Accepted for publication June 20, 2000 chronic rejection have not been defined.
The present model was chosen because either progres-Ó 2000 by the International Society of Nephrology
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sion to chronic rejection or recovery from acute rejection nation. The biopsies samples were diagnosed using Na-
tional Institutes of Health-Cooperative Clinical Trialsoccurs spontaneously after the same initial treatment.
This model thus provides a novel opportunity to assess in Transplantation (NIH-CCTT) classification of renal
allograft rejection [14–16].the key pathogenetic features that predict or accompany
progression to chronic rejection after acute rejection. To clarify the phenotypes of infiltrating cells, frozen
sections were stained by the standard avidin-biotin-horse-We compared the intragraft events in acute rejection
and thereafter in those that develop chronic rejection radish-peroxidase complex (ABC) technique [17]. Pri-
mary antibodies included anti-pig monoclonal antibodiesand those that recovered, focusing on (1) the phenotypic
characteristics, (2) activation, (3) proliferation, (4) apo- MSA4 (IgG2a, anti-swine CD2), BB23-8E6 (IgG2b, anti-
swine CD3), 74-12-4 (IgG2b, anti-swine CD4), 76-2-11ptosis in graft infiltrating cells, and (5) humoral and cell-
mediated graft cell injury. (IgG2a, anti-swine CD8), BB6-11C9 (IgG1, anti-swine
CD21; B cells), K231-3B2 [IgG1, anti-swine interleukin-2
receptor (IL2R)], and 74-22-15A (IgG1, macrophages)
METHODS
[18], and anti-human CD3 polyclonal antibodies (Dako,
Animals, surgery, and immunosuppression Glostrup, Denmark). The anti-human CD3 antibody was
confirmed to react with swine pan T cells using swineTransplant donors and recipients were selected from
our herd of partially inbred Massachusetts General Hos- thymus, lymph nodes, and spleen.
For the detection of proliferating cell nuclear antigenpital (MGH) miniature swine at five to seven months of
age. The immunogenetic characteristics of this herd and (PCNA), 10% buffered formalin-fixed, paraffin-embed-
ded tissue blocks were used, and sections were stainedof the intra-MHC recombinant haplotypes available
have been described previously [1, 2]. Recombinants using ABC technique. In order to optimize detection of
PCNA, microwave treatment (heat for 2 3 5 minutes inswine lymphocyte antigen (SLA)gg (class Ic/c, class IId/d)
animals were donors, and SLAdd (class Id/d, class IId/d) 0.01 mol/L sodium citrate, pH 6.0, in a 750 W microwave
oven at full power and then immediately chilling to 48C)animals were recipients of orthotopic kidney grafts, in
order to achieve a transplantation of SLA class II- and 1/1000 dilution of PC10 (IgG2a; Dako) was used
[19]. Double immunostaining for PCNA and CD3 wasmatched, 2-haplotype class I-mismatched kidneys, as de-
scribed previously [4–6]. In all animals, a complete (N 5 performed in formalin-fixed paraffin sections using a
two-color staining technique [17]. The sections were first6) or partial (N 5 2) thymectomy was carried out 21
to 42 days before kidney transplantation, as described stained with PCNA and incubated with alkaline phos-
phatase-labeled anti-mouse IgG (Vector, Burlingame,previously [5, 6]. CsA was provided by Novartis Pharma-
ceutical Corp. (Hanover, NJ, USA), and was adminis- CA, USA) with a blue reaction product (Alkaline Phos-
phatase Substrate Kit III; Vector). Sections were thentered daily as a single infusion at a dose of 10 to 13
mg/kg (adjusted to maintain a blood level of 400 to 800 stained with polyclonal CD3, horseradish peroxidase-
labeled anti-goat antibody (Dako), hydrogen peroxideng/mL) for 12 consecutive days, starting on the day of
kidney transplantation. The plasma creatinine (Cr) level (H2O2) containing 3,39-diaminobendizine (DAB; Re-
search Genetics, Hansville, AL, USA), which has awas monitored to indicate graft function.
Based on clinical course, we divided the animals into brown reaction product. Controls included omission or
substitution of the primary antibodies with irrelevanttwo groups: one progressed to chronic rejection by day
100 (progression group), and the other recovered from antibodies.
To detect antibody deposition in grafts, frozen tissueacute rejection (recovery group). Four thymectomized
(three complete and one partial) animals were in the sections were stained with fluorescein isothiocyanate
(FITC)-conjugated goat anti-swine IgG or IgM (bothprogression group, and another four (three complete and
one partial) animals were in the recovery group. The from Kirkegaard & Perry Laboratories, Gaithersburg,
MD, USA) and examined in an epifluorescence micro-morphological and molecular markers were quantitated
and compared in serial biopsies from grafts in the two scope (Zeiss, Oberkochen, Germany).
In histologic sections, fragmented nuclear DNA asso-groups.
ciated with apoptosis and sometimes necrosis was labeled
Histologic examination by terminal deoxynucleotidyl transferase (TdT)-medi-
ated dUTP-biotin nick end labeling (TUNEL) methodIn both the progression and the recovery groups, se-
quential wedge kidney biopsies were performed on post- [20]. After deparaffinized and incubated with proteinase
K 100 mg/mL for 15 minutes, sections were rinsed inoperative days 8, 11, 18, 30, 60, and 100 and at spontane-
ous death. For light microscopic examination, tissue was TdT buffer and incubated with TdT 1:25 and biotinyl-
ated-dUTP 1:20 in TdT buffer for 60 minutes at 378C. Thefixed in 10% buffered formalin and was embedded in
paraffin. Hematoxylin and eosin (HE) and periodic acid- biotinylated nuclei were detected with avidin peroxidase
and H2O2 containing DAB. Double immunostaining withSchiff (PAS) stains were performed for histologic exami-
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TUNEL and CD3 for the identification of the origin
of TUNEL1 cells was performed, by immunoalkaline
phosphatase using TUNEL, followed by an antibody to
CD3, horseradish peroxidase-labeled antigoat, and then
incubated with H2O2 containing DAB. Controls con-
sisted of omission of the dUTP or TdT.
Quantitation of histologic findings
Morphometric studies were performed to determine
the number of CD2-, CD3-, CD4-, CD8-, or CD21-posi-
tive cells and macrophages per mm2, as well as the per-
centage of graft infiltrating cells that were PCNA1,
IL2R1, or TUNEL1. In addition, the frequency of
TUNEL1 graft parenchymal cells was measured in tubu-
lar epithelial cells, glomeruli, and peritubular and arterial
endothelium, in order to detect ongoing antibody- and
Fig. 1. Graft function in the progression (d) and the recovery (s)cell-mediated graft cell injury. More than 40 fields of
groups. In the progression group, four animals developed long-term
renal cortex (at 3400, using an optical grid area of 0.0625 loss of graft function. In the recovery group, four animals showed a
transient elevation in plasma creatinine (Cr) 18 to 40 days post-trans-mm2) and more than 40 glomerular cross sections and
plant, but gradually improved and had stable renal function remainingall arterial cross sections in all fields of the renal cortex
thereafter.
were counted in each kidney sample without prior
knowledge of the clinical or histologic findings. Counts
were expressed as the numbers of positive cells per mm2,
the number of positive cells per glomerular cross section, Flow cytometry
the percentage of the infiltrating cells, or the percentage The presence of antidonor class I (SLA class Ic/c) IgM
of the arteries affected. These results were expressed as and IgG in the serum of experimental swine was detected
the mean 6 SD or SEM, and statistical analysis was by indirect flow cytometry using a Becton-Dickinson
performed using the unpaired Student’s t-test. FACScan (Sunnyvale, CA, USA) [6] and recombinant
SLA PBL to determine the SLA-binding specificity ofCell-mediated lympholysis assay
the antibody. For staining, 1 3 106 cells per tube of
Cell-mediated lympholysis (CML) assays were per- recombinant SLA PBL or donor-type PBL (SLAgg, class
formed, using peripheral blood leukocytes (PBLs), as Ic/c, class IId/d) were resuspended in Hank’s balanced salt
described previously [4–6]. Briefly, lymphocyte cultures solution (Life Technologies, Grand Island, NY, USA)
containing 4 3 106 responder and 4 3 106 irradiated containing 0.1% bovine serum albumin (BSA) and
(25G) stimulator PBL in 2 mL of medium were incubated 0.05% NaN3, and incubated for 30 minutes at 48C with
for six days at 378C in 7.5% CO2 and 100% humidity. decomplemented test sera. FITC-labeled goat anti-swine
Bulk cultures were harvested, and effector cells were IgM or IgG polyclonal antibodies were used as secondary
tested on 51Cr-labeled blasts. The tests were run at seri- reagents (Pharmagen). After a final wash, cells were
ally diluted ratios (100:1, 50:1, 25:1, 12.5:1). After 5.5 analyzed by flow cytometry using propidium iodide gat-
hours of effector cell incubation with the 5 3 103 specific ing to exclude dead cells. Both normal pig serum and
targets, supernatants were harvested, and 51Cr release pretransplant sera from each respective experimental
was determined on a gamma counter (Micromedics, animal were used to assure specific binding. The data
Huntsville, AL, USA). Maximum lysis was obtained with were expressed as median fluorescence intensity, and the
a 1% solution of the nonionic detergent NP-40 (BLR, results in the progression and the recovery groups were
Rockville, MD, USA). Baseline levels were measured expressed as the mean 6 SD.
as the rate of spontaneous release of 51Cr from 5 3 103
targets. The data were expressed as percentage of specific
RESULTSlysis:
Of the eight animals that underwent complete (N 5% specific lysis 5
6) or partial (N 5 2) thymectomy 21 to 42 days before
transplant, all developed graft dysfunction in the earlyexperimental release (cpm) 2 spontaneous release (cpm)
maximum release (cpm) 2 spontaneous release (cpm) 3 100 phase (Fig. 1). Thereafter, a markedly different clinical
course was observed in these animals. Four thymecto-The results of the progression and the recovery groups
mized (three complete and one partial) animals had pro-were expressed as the mean 6 SD, and statistical analysis
was performed using the unpaired Student’s t-test. longed graft dysfunction between days 18 and 40, but
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Fig. 2. Recovery group. Recovery from acute rejection (type II) is shown with PAS (3125; A–D) and CD31 stains (3250; E–H) on days 18 (A
and E), 30 (B and F), 60 (C and G), and 100 (D and H). A diffuse mononuclear cell and CD31 cell infiltrate is seen with tubulitis, acute allograft
glomerulopathy, and endarteritis at day 18. Thereafter, the T cells diminish, and allografts recover from acute rejection leaving minimal interstitial
fibrosis by day 100.
gradually improved spontaneously and subsequently had During the acute rejection in the recovery group, be-
tween day 8 and day 18, many graft infiltrating cellsstable renal function for a long time (.day 100, recovery
group). The other four (three complete and one partial expressed PCNA (Fig. 3A). Double staining revealed
CD31 cells that frequently expressed PCNA (Fig. 3B),thymectomized) animals developed progressive renal
dysfunction (progression group); two died from uremia indicating that many infiltrating T cells were proliferating
in the grafts. IL2R1 infiltrating cells were found diffuselywith massive proteinuria on day 42 and day 51. The
morphological and immunologic markers were examined in the cortex on day 18 (Fig. 3C). IgG and IgM deposition
was found in glomeruli, small arteries, and focal peritu-in serial biopsies taken from grafts in the progression
group and compared with grafts in the recovery group. bular capillaries (Fig. 3D). These findings indicated that
T-cell– and possibly antibody-mediated acute vascular
Recovery group: Resolution of type II acute rejection rejection occurred in the acute phase, even in the recov-
ery group. However, during the resolution process, byInitially, the recovery group had diffuse mononuclear
cells, including CD31 cells, which infiltrated the intersti- day 60, PCNA1, PCNA1 CD31, and IL2R1 graft infil-
trating cells diminished rapidly (Fig. 3 E–G), and onlytium, tubules, glomeruli, and small arteries on days 8
through 18 with tubulitis, acute allograft glomerulopathy, rare deposition of IgM and IgG was then detectable in
the grafts (Fig. 3H).and endarteritis (Fig. 2A, E). However, the mononuclear
cell and CD31 cell infiltrate gradually diminished with
Progression group: Evolution of acute rejectionless prominent tubulitis by day 30 (Fig. 2 B, F). Thereaf-
to chronic rejectionter, acute allograft glomerulopathy and arterial lesions
resolved with segmental glomerular hypercellularity, In the progression group, a similar extent of acute
rejection and CD31 cell infiltration was observed in theminimal interstitial fibrosis, and mononuclear cell infil-
trate (Fig. 2C, D, G, H). All allografts showed normal early phase (Fig. 4A, E). The diffuse interstitial mononu-
clear cell and CD31 cell infiltration continued to day 30arteries by day 100.
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Fig. 3. Recovery group. Proliferating cell nuclear antigen1 (PCNA1) cells (A and E ), PCNA and CD31 cells (B and F ), interleukin-2 receptor1
(IL2R1) cells (C and G ), and immunoglobulin G (IgG) deposition (D and H) in renal allografts on days 18 (A–D) and 60 (E–H). Many proliferating
and activated infiltrating cells, numerous proliferating T cells, and intense glomerular IgG deposition are seen on day 18; however, these progressively
diminish after acute rejection by day 60 [A and E: PCNA stain, 3400; B and F: double stain with PCNA (black) and CD3 (brown), 3800; C and
G: IL2R stain, 3500; D and H: IgG stain, 3400].
with the development of acute allograft glomerulopathy equivalent in all time points in the progression and the
recovery groups. A few CD211 B cells infiltrated allo-and endarteritis (Fig. 4B, F). Subsequently, the mononu-
clear cell and CD31 infiltrate gradually resolved; how- grafts in the progression group, and the number was not
different from the recovery group.ever, the glomerulopathy, vasculopathy, and interstitial
fibrosis progressed by day 60 (Fig. 4C, G). By day 100, Prominent PCNA1, PCNA1 CD31, and IL2R1
graft infiltrating cells were seen in grafts with acute typethe allografts had morphologic findings characteristic of
chronic rejection (Fig. 4D, H). The grafts from the two II rejection in the progression group (Fig. 6A–C), and
these persisted during the development of chronic rejec-dead animals also morphologically showed the process
of chronic rejection. tion (Fig. 6 E–G). Markers of proliferation (PCNA1)
and activation (IL2R1) in graft infiltrating cells in theMononuclear cell lineages were assessed by immuno-
histochemistry (Fig. 5). In the progression and the recov- early phase (day 8 to day 18) were not significantly differ-
ent in the progression and the recovery groups (Fig. 7A,ery groups, acute rejection with a similar number of
T cells and macrophages occurred at the early phase. B). Thereafter, significantly more PCNA1 and IL2R1
cells remained in the progression group (day 30 to dayThereafter, the numbers of macrophage and T-cell sub-
sets (CD2, CD3, CD4, and CD81 cells) were all signifi- 100). In contrast to the recovery group, IgG deposition in
glomeruli, small arteries, and focal peritubular capillariescantly greater in the progression group between day 30
to day 100. The proportions of each T-cell subset were continued through the chronic phase (Fig. 6D, H).
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Fig. 4. Progression group. The development of chronic rejection is shown with PAS (3125; A–D) and CD3 (3250; E–H) stains on days 18 (A
and E), 30 (B and F), 60 (C and G), and 100 (D and H). Acute rejection (type II) occurs with a diffuse mononuclear cell and CD31 cell infiltrate,
tubulitis, acute allograft glomerulopathy, and endarteritis at day 18. The cell infiltrate continues with the development of allograft glomerulopathy
and arteriopathy at day 30 to day 60. Subsequently, typical histologic chronic rejection develops by day 100.
TUNEL1 graft infiltrating cells and E–H). Significant differences in the number of TUNEL1
graft parenchymal cells cells in tubules, glomeruli, peritubular capillaries, and
arteries were evident at day 60 between the progressionNumerous TUNEL1 infiltrating cells, many of which
and the recovery groups (Fig. 10), indicating that activealso expressed CD3, were observed (Fig. 8) in the pro-
graft cell injury continued through the chronic phase ingression and the recovery groups. The TUNEL1 graft
the progression group.infiltrating cells peaked at day 18 and gradually de-
creased thereafter. The frequency of TUNEL1 infiltrat-
Cell-mediated cytotoxicitying cells in the progression group was slightly higher than
In the recovery group, antidonor cytotoxic T lympho-in the recovery group, although the difference was not
cyte (CTL) reactivity gradually decreased by day 100statistically significant between day 8 to day 60.
(Fig. 11A). However, in the progression group, the CTLIn both the progression and the recovery groups, promi-
reactivity maintained similar levels to the pretransplantnent TUNEL1 parenchymal cells were seen associated
levels by day 60 and was significantly higher than in thewith CD31 cells in the lesions of tubulitis, allograft glom-
recovery group. The last samples (day 100) showed onlyerulopathy, peritubular capillary, and endarteritis during
low levels of CML in both groups.acute rejection. Thereafter, in the progression group,
numerous TUNEL1 cells remained in these lesions dur-
Immunoglobulin responseing the development of chronic rejection (Fig. 9A–D).
The presence of the antidonor specific class I antibodyIn contrast, TUNEL1 cells in these sites progressively
diminished in the recovery group by day 100 (Fig. 9 in serum by flow cytometric analysis was correlated with
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Fig. 5. Graft infiltrating cells. The graft (A) CD31, (D) CD81, (E ) CD4, and (B) CD21 cell, and macrophage infiltrate continues in the progression
group (d) and gradually resolves in the recovery group (s). The number of each subset (excluding CD211 B cells, F ) in the progression group
is significantly higher than in the recovery group between day 30 to day 100, but the proportion of each subset is similar. (C ) Macrophages. (A–F )
Values are expressed as mean 6 SEM. *P , 0.05; **P , 0.01; *** P , 0.001.
antibody deposition in the grafts (Fig. 11B, C). In both arteriopathy during the development of chronic rejection
[7, 21–24]. However, more typical chronic rejection (atgroups, transient antidonor IgM and IgG in serum was
least in mice) is associated with the presence of humoraldetected. Antidonor class I IgG in serum progressively
reactivity to the donor [24, 25]. Consistent with this hy-decreased in the recovery group by day 60, whereas it
pothesis, in the present model, IgG deposition in thewas detected in serum through day 60 in the progression
grafts persisted in the progression group, and antidonor-group. Later samples (day 100) had no detectable anti-
specific class I antibody remained in the circulation forbody in either group.
60 days. Although anticlass I antibody can mediate acute
humoral rejection [26, 27], our results suggest that it is
DISCUSSION also associated with the development of chronic rejec-
In this study, we demonstrated that persistent immu- tion.
nologic activation and immunologic injury of graft paren- Substantial evidence indicates that T cells also play a
chymal cells (tubules, glomeruli, peritubular capillaries, critical role in the development of chronic rejection, on
and small arteries) distinguish those grafts that progress their cytotoxity and production of cytokines [21, 22, 28,
to chronic rejection. Chronic rejection, sometimes re- 29]. Many strategies that inhibit the T-cell–mediated re-
ferred to as “chronic allograft nephropathy,” remains one sponse also reduce arterial intimal thickening in chronic
of the most important causes of graft loss after the first rejection [30–32]. Macrophages are believed to play a
year. However, the pathogenesis of chronic rejection critical role in chronic rejection by their secretion of
remains unclear [7–10]. Recent studies have indicated various products, including cytokines, oxygen radicals,
and growth factors [33, 34]. The infiltration of greaterthat either antibody or T cells can incite the chronic
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Fig. 6. Progression group. PCNA1 cells (A and E ), PCNA and CD31 cells (B and F ), IL2R1 cells (C and G), and IgG deposition (D and H)
on days 18 (A–D) and 60 (E–H). Many proliferating and activated infiltrating cells, numerous proliferating T cells, and intense glomerular IgG
deposition are seen on day 18. Thereafter, these continue by day 60 with the development of chronic rejection [A and E: PCNA stain, 3400; B
and F: double stain with PCNA (block) and CD3 (brown), 3800; C and G: IL2R stain, 3500; D and H: IgG stain, 3400].
Fig. 7. Percentage of PCNA1 (A), IL2R1 (B), and TUNEL1 (C ) graft infiltrating cells in the progression (d) and the recovery (s) groups.
Mononuclear cell proliferation and activation persist in the progression group by day 100, and these cells are significantly higher in the progression
group between day 30 and day 100. The frequency of TUNEL1 infiltrating cells in the progression group is slightly higher than in the recovery
group, although the difference is statistically significant only at day 100. (A and B) Values are expressed as mean 6 SD. (C) Values are expressed
as mean 6 SEM. *P , 0.05; **P , 0.01; ***P , 0.001.
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lysis and apoptosis) of MHC incompatible cells [39–41].
Antibody- and complement-mediated cell injury may
also play an important role by lysis of target cells by
terminal complement components [42, 43]. The TUNEL
method can detect DNA fragmentation in the process
of apoptosis and cell necrosis [20, 44]. Therefore, the
TUNEL method may be quite practical in the detection
of injured cells in graft by antibody- and cell-mediated
rejection. In this study, we have demonstrated that sig-
nificant and persistent injury of graft parenchymal cells
(tubules, glomeruli, peritubular capillaries, and small ar-
teries) was associated with the development of chronic
rejection. Persistent immunologic cytotoxicity is proba-
bly a central mechanism in the pathogenesis of chronic
rejection in this model.
Fig. 8. Apoptosis in graft infiltrating cells in the progression group on In both groups, a similar degree of acute rejection
day 60. TUNEL stain (3500; A) and double stain with TUNEL method occurred between day 8 and day 18. Thereafter, signifi-(black) and CD3 (brown, 3800; B) show the numerous TUNEL1
cant differences in antibody deposition, the frequencyapoptotic infiltrating cells (arrow) and TUNEL1 CD31 apoptotic infil-
trating T cells (arrow). of PCNA1 or IL2R1 leukocytes and TUNEL1 graft
parenchymal cells were evident as early as day 30 to day
60 between the progressing and the recovery groups,
suggesting that the analysis of sequential graft biopsies
numbers of T cells and macrophages into the grafts in during the acute episode (day 8 to 18) and three weeks
the progression group in our study is compatible with or more after an acute rejection episode may predict
this view. However, the T-cell phenotype was similar in chronic rejection (or recovery) better than a biopsy only
the progression and the recovery groups, so that the during the acute phase.
phenotypic characteristics of the infiltrate had neither As noted previously in this article, acute rejection is
prognostic or diagnostic significance. strongly related to the development of chronic rejection.
The extent of TUNEL1 apoptotic graft infiltrating cells However, not all acute rejection leads to chronic rejec-
had little or no diagnostic value in predicting chronic rejec- tion. Our study of the recovery group demonstrated that
tion, since the difference in the frequency of TUNEL1 the injured allografts gradually recovered even from type
infiltrating cells was not statistically significant between II acute rejection. This was associated with a reduction of
the progression and the recovery groups on day 8 to day antidonor class I antibody, resolution of graft infiltrating
60. Apoptosis of graft infiltrating cells may regulate the cells with immune activation, and diminished immune-
number of infiltrating cells, including donor reactive T mediated graft cell injury. It is notable that recovery from
cells, and cell-mediated antigraft activity may associate severe acute rejection occurred with the development of
with activation-induced and alloantigen-induced cell tolerance, without exogenous additional immunosup-
death of T lymphocytes [35]. In the present study, infil- pression. Even in the recovery group, the early phase
trating T cells undergo apoptosis. However, the rate of had antidonor class I IgG production, prominent T-cell
proliferation, influx or efflux, rather than apoptosis, infiltrate with immune activation, and persistent im-
probably determines the net accumulation of T cells in mune-mediated graft injury, indicating that tolerance in-
the graft. duction is incomplete, associated with a break of thymic
Indeed, increased levels of PCNA and IL2R1 mono- mechanisms for tolerance by thymectomy. However, thy-
nuclear cells were present during the development of mectomized animals still have peripheral mechanisms
chronic rejection. Recent reports demonstrate that acti- for tolerance [5, 6]. Peripheral tolerance may promote
vation and proliferation of graft infiltrating cells could clonal deletion or anergy of alloreactive T cells and could
be useful in differentiating between rejection and other be mediated by a change in cytokine milieu or by sup-
causes of graft dysfunction [36–38]. We found that persis- pressive mechanisms. Indeed, in the present study, our
tent IL2R1 and PCNA1 cells precede the development results indicate that loss of T cells by apoptosis (T-cell
of chronic rejection. Therefore, analysis of proliferation deletion) and limiting the proliferation, activation, and
and activation of infiltrating leukocytes may be more cytotoxicy of infiltrating T cells (T-cell anergy) were evi-
useful in differentiating between progressing to failure dent in the grafts. In our class I-mismatched renal allo-
and recovering grafts after acute rejection. graft model, even in the nonthymectomized animals, it
T-cell–mediated cytotoxicity probably plays an impor- is likely that an alteration in cytokine production plays
an important role in the induction of tolerance, sincetant role in allograft rejection by the destruction (cell
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Fig. 9. Double stain with TUNEL method (black) and CD3 (brown) in tubulitis (A and E ), glomerulopathy (B and F ), peritubular capillaries
(C and G ), and endarteritis (D and H) in the progression (A–D) and the recovery (E–H) groups on day 60 (3900). In the progression group,
numerous TUNEL1 cells (arrow) are observed with many CD31 cell infiltration. However, less prominent CD31 cells and TUNEL1 cells are
seen in the recovery group.
inhibition of T-cell help (IL-2) by CsA leads to long- Recent studies in rodent and large animal models dem-
term tolerance [2, 4], and altered cytokine production onstrate that various strategies for tolerance induction
consistent with differential activation of Th1 and Th2 prevent development of chronic rejection [49, 50]. In
cells has been demonstrated in renal tissue from allo- contrast, the progression group in our study suggests that
grafts [45, 46]. The graft infiltrate also contains immuno- if tolerance induction to allografts was delayed (or did
regulatory cells important in the adaptation of the host not occur), persistent immunologic graft injury leads to
to the graft [47]. Also, a recent report from the other chronic rejection. We therefore conclude that in treat-
laboratory shows that chronically rejected rat kidney ment using the tolerant induction protocol, rapid and
allografts can paradoxically induce donor-specific toler- stable tolerance induction is important for long-term sta-
ance [48]. In the recovery group, the mechanisms of self-
ble graft acceptance, before critical steps in the processlimited cellular as well as humoral immunity and the
of chronic rejection become established. Our resultsdevelopment of tolerance during acute rejection are still
show that the immune activation resolved by day 60 inunclear and are the subject of continuing investigations
the recovery group, although active immune-mediatedin our laboratory. However, it appears that cell- and
graft injury continued to at least day 60 in the progressionantibody-mediated acute rejection may resolve during
group. Thus, day 60 after transplantation is a turningthe development of transplant tolerance (without antire-
point for either recovery from rejection and long-termjection therapy), and injured graft associated with cell-
graft acceptance or progression to chronic rejection inand antibody-mediated rejection may recover to long-
term functioning graft. this tolerance-induction protocol.
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Fig. 10. TUNEL1 cells in tubules (A), glo-
meruli (B), peritubular capillaries (C ), and
arteries (D) in the progression (d) and the
recovery (s) groups. TUNEL1 graft paren-
chymal cell injury continues in the progression
group, and the number of TUNEL1 cells is
significantly higher than in the recovery group
on day 60. In the recovery group, TUNEL1
cells progressively reduce by day 100. Values
are expressed as mean 6 SEM. *P , 0.05;
**P , 0.01; ***P , 0.001.
Fig. 11. Circulating anti-donor reactive cytotoxic T lymphocyte (CTL; A) and anti-donor class I IgM (B) and IgG (C ) in the progression (d) and
the recovery (s) groups. Cell-mediated ML assay (A) shows that the anti-donor CTL reactivity is higher in the progression group by day 60
(effector:target ratio is 100:1). Flow cytometric analysis for detection of the anti-donor class I antibody (B and C) shows that transient anti-donor
class I IgM and IgG in serum are seen in the recovery group. However, anti-donor class I IgG production continued through day 60 in the
progression group. Values are expressed as mean 6 SD. *P , 0.05; **P , 0.01; ***P , 0.001.
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